Health Minister Mark Butler confirmed on 16 July 2026 that three multiple sclerosis drugs — Ocrevus, Kesimpta and Lemtrada — will stay subsidised on the Pharmaceutical Benefits Scheme, ending weeks of uncertainty for MS patients and their specialists. Butler backed the continued listings on clinical grounds, saying the drugs' benefits justified keeping them taxpayer-funded while a formal review of MS drug use goes ahead.

The reprieve is temporary. The Pharmaceutical Benefits Advisory Committee (PBAC) — the independent expert body that advises the government on which drugs to list on the PBS — has called for a rapid review of MS drug use to be finished before the end of 2026. A final decision on the listings will be made after that.

The dispute that brought Butler into the picture started in late 2025, when a new drug called Briumvi, made by TG Therapeutics, was added to the PBS at a lower cost than the existing treatments. Australia's PBS uses a system called reference pricing: when drugs treat the same condition and sit in the same class, the government ties what it pays for all of them to the cheapest one. Think of it like a price-matching scheme — the cheapest drug sets the benchmark, and every other drug in that group gets its price pulled down to match.

Briumvi's lower price automatically dragged down the reference price for Kesimpta (made by Novartis) and Ocrevus (made by Roche), cutting what the government would pay for those established drugs.

Roche's general manager, Dr Nic Horridge, said the reference pricing cut "would make it impossible to keep Ocrevus on the PBS." That's the standard pharmaceutical-industry response when reference pricing bites: the manufacturer signals it will withdraw supply rather than accept the lower price, framing the pullout as commercially unavoidable. Whether that threat is a genuine deal-breaker or just a negotiating tactic is the question PBAC's rapid review will need to sort out before year's end.

The money involved explains why the manufacturers are nervous. Under the PBS, a monthly dose of Kesimpta costs the Commonwealth AU$2,231. A course of ocrelizumab (Ocrevus) costs AU$16,500. In the United States, Kesimpta can cost more than US$10,000 per month. The contrast is stark, and it's exactly the comparison the PBS is built to produce: Australians pay a fraction of the US list price because the government negotiates as a single bulk buyer on behalf of the whole country. That buying power is the backbone of the scheme, and reference pricing is one of the tools that keeps costs down.

The tension here is structural, not accidental. Reference pricing is how the PBS passes the savings from a new, cheaper drug on to the taxpayer: a lower-cost drug arrives, prices across the group fall, and the government's bill shrinks. But if the makers of the established drugs decide the new reference price is too low to accept, the mechanism can backfire — producing fewer options on the scheme, not cheaper ones. Patients then either switch treatments or face the full cost privately.

ABC News reported on 8 July 2026 that the pricing dispute could result in Ocrevus and Kesimpta being pulled from the PBS, potentially leaving MS patients with large out-of-pocket costs. MS Australia publicly acknowledged the coverage via its official Facebook account the following day, a sign the patient advocacy sector was watching the issue closely.

Lemtrada's inclusion in Butler's confirmation is worth noting. Lemtrada was not directly caught in the Briumvi reference-pricing chain, and its appearance in the minister's statement alongside Ocrevus and Kesimpta suggests the PBAC review will look across the whole MS drug class broadly, rather than just at the specific products caught in Briumvi's pricing wake.

For the roughly 33,000 Australians living with MS, the immediate pressure is off. Ocrelizumab and ofatumumab remain accessible at PBS-subsidised rates. But the PBAC review timeline is tight, and the reference-pricing mechanism that caused the problem hasn't changed. A cheaper drug entering the class will keep pulling prices down for every other drug in it. The question for the review is whether the government can hold the cost-saving logic of reference pricing together with the clinical reality that patients on established therapies don't always tolerate or respond to alternatives.

Butler has, in effect, bought time. The clinical-benefit argument is sound as far as it goes: these drugs reduce relapse rates and slow disease progression in relapsing-remitting MS, and disrupting patients' treatment regimens carries genuine clinical risk. But "clinical benefit" is not a pricing mechanism. By year's end, PBAC will need to have reconciled the reference-price arithmetic with the therapeutic case for keeping multiple products listed, or Butler will be back at the dispatch box explaining why a cost-containment tool designed to save the PBS money has instead narrowed patient access.

The broader context here is that the government's preferred outcome is obvious: Briumvi's cheaper price flowing through to lower PBS spending across the MS class, without any manufacturer walking away. Whether the manufacturers' threshold prices and the PBAC's reference price can land on a number that delivers both is the only question that matters between now and December.